# A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy

> **NCT05937152** · PHASE2 · WITHDRAWN · sponsor: **Mayo Clinic**

## Conditions studied

- Diabetic Polyneuropathy

## Interventions

- **DRUG:** Eptinezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05937152
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no participants enrolled
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05937152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05937152, "A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05937152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*